Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome
- Conditions
- Gorlin Syndrome
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06050122
- Locations
- 🇺🇸
Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
🇺🇸Center for Dermatology Clinical Research, Fremont, California, United States
🇺🇸University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location, Los Angeles, California, United States
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
- Conditions
- Papulopustular Rosacea
- Interventions
- Drug: Encapsulated Benzoyl Peroxide Cream
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05675501
- Locations
- 🇺🇸
Integrative Skin Science and Research (ISSR), Sacramento, California, United States
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT04308395
- Locations
- 🇬🇧
PellePharm Investigative Site, Oxford, United Kingdom
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Pellepharm Investigative Site, Ann Arbor, Michigan, United States
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
- Conditions
- Recurrent Basal Cell Carcinoma
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT04155190
- Locations
- 🇺🇸
Axiom Research, LLC, Colton, California, United States
🇺🇸Center for Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT04059523
- Locations
- 🇺🇸
DermResearch, Inc., Austin, Texas, United States
🇺🇸J&S Studies, Inc, College Station, Texas, United States
- Prev
- 1
- 2
- 3
- Next
News
Sol-Gel and Mayne Pharma Announce $16 Million Deal for EPSOLAY and TWYNEO Rights in the U.S.
• Sol-Gel Technologies has entered into a $16 million agreement with Mayne Pharma for the sale and exclusive license of U.S. rights to dermatology products EPSOLAY and TWYNEO, extending the company's cash runway into Q1 2027. • The transaction allows Sol-Gel to focus resources on its promising SGT-610 program for Gorlin syndrome, which has completed 80% patient recruitment for Phase III trials with top-line results expected in Q4 2026. • Based on recent market research, Sol-Gel estimates SGT-610's U.S. market potential between $400-500 million annually as the first potential preventative treatment for basal cell carcinomas in Gorlin syndrome patients.
Androgenetic Alopecia Pipeline Shows Promise with Over 100 Therapies in Development
DelveInsight's latest report reveals a robust pipeline for androgenetic alopecia with 80+ companies developing 100+ therapeutic candidates across various clinical stages.
Rosacea Therapeutics Pipeline Shows Promise with Emerging Therapies
Over 25 companies are developing novel rosacea treatments, indicating a robust pipeline.
Sol-Gel Technologies Receives Nasdaq Extension to Regain Compliance
Sol-Gel Technologies received a 180-day extension from Nasdaq to regain compliance with the minimum bid price rule, now until May 19, 2025.
Sol-Gel Technologies Advances SGT-610 for Gorlin Syndrome and SGT-210 for Darier Disease
Sol-Gel's Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is actively enrolling patients across 40 clinical sites, with topline results expected in H2 2026.
Rosacea Therapeutics: Emerging Therapies and Market Outlook
Over 25 companies are actively involved in developing novel rosacea treatments, indicating a robust pipeline.
FDA Approves Epsolay for Inflammatory Lesions of Rosacea
• The FDA has approved Epsolay, a 5% encapsulated benzoyl peroxide cream, for treating inflammatory lesions of rosacea in adults. • Clinical trials showed Epsolay reduced inflammatory lesions by nearly 70% after 12 weeks, compared to 38-46% with the vehicle cream. • Almost 50% of patients achieved an IGA score of 0/1 at 12 weeks, indicating clear or almost clear skin, compared to placebo. • Epsolay utilizes microencapsulation technology to slowly release benzoyl peroxide, potentially reducing skin irritation.